Avalyn Pharma Expands Executive Team with Appointment of Howard M. Lazarus, MD, FCCP to the Role of Chief Medical Officer
Dr. Lazarus brings valuable clinical and drug-development experience to the Avalyn executive team.
- Dr. Lazarus brings valuable clinical and drug-development experience to the Avalyn executive team.
- "Howard’s appointment comes at a critical time in our clinical development," explained Lyn Baranowski , Avalyn’s CEO.
- In that role, he diagnosed and treated patients with complex pulmonary vascular and interstitial diseases such as IPF and PAH.
- I’m looking forward to working with the team to advance these product candidates into additional clinical trials and along their path towards approval by the regulatory agencies.”